TKM-PLK1 leaped into human trials by recruiting patients with lymphoma and other solid tumors including advanced adrenocortical carcinoma (ACC), and hepatocellular carcinoma (HCC). This evidence concerns the gene PLK1 and adrenal cortex carcinoma.